Literature DB >> 23526433

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Guranda Chitadze1, Marcus Lettau, Jaydeep Bhat, Daniela Wesch, Alexander Steinle, Daniel Fürst, Joannis Mytilineos, Holger Kalthoff, Ottmar Janssen, Hans-Heinrich Oberg, Dieter Kabelitz.   

Abstract

The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) with the corresponding natural killer group 2, member D (NKG2D) receptor triggers cytotoxic effector activity of natural killer cells and certain T-cell subsets and provides a costimulatory signal for cytokine production. Thus, the presence of MICA/B on transformed cells contributes to tumor immunosurveillance. Consequently, the proteolytic cleavage of MICA/B is regarded as an important immune escape mechanism of various cancer cells. To investigate the molecular machinery responsible for the shedding of endogenous MICA/B, we analyzed different human tumor entities including mammary, pancreatic and prostate carcinomas. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) revealed that all tested tumor cells constitutively expressed MICA and MICB on the cell surface and also released NKG2D ligands into the supernatant. We demonstrate that the "a disintegrin and metalloproteases" (ADAMs) 10 and 17 are largely responsible for the generation of soluble MICA/B. Pharmacological inhibition of metalloproteases reduced the level of released MICA/B and increased cell surface expression. Studies using RNA interference not only revealed a prominent role of ADAM10 and ADAM17 in NKG2D ligand shedding but also a tumor cell-specific role of ADAM10 and/or ADAM17 in shedding of MICA or MICB. Moreover, we report that in the prostate carcinoma cell line PC-3, MICA was not shed at all but rather was secreted in exosomes. These data indicate that the release of NKG2D ligands from individual tumor entities is by far more complex than suggested in previously reported MICA/B transfection systems.
© 2013 UICC.

Entities:  

Keywords:  ADAM10; ADAM17; MICA; MICB; NKG2D ligands; shedding

Mesh:

Substances:

Year:  2013        PMID: 23526433     DOI: 10.1002/ijc.28174

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  82 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Authors:  Jaydeep Bhat; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2015-04-28       Impact factor: 8.110

3.  In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.

Authors:  Guranda Chitadze; Charlotte Flüh; Elgar Susanne Quabius; Sandra Freitag-Wolf; Christian Peters; Marcus Lettau; Jaydeep Bhat; Daniela Wesch; Hans-Heinrich Oberg; Stefanie Luecke; Ottmar Janssen; Michael Synowitz; Janka Held-Feindt; Dieter Kabelitz
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

4.  Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.

Authors:  Denise P Muñoz; Steven M Yannone; Anneleen Daemen; Yu Sun; Funda Vakar-Lopez; Misako Kawahara; Adam M Freund; Francis Rodier; Jennifer D Wu; Pierre-Yves Desprez; David H Raulet; Peter S Nelson; Laura J van 't Veer; Judith Campisi; Jean-Philippe Coppé
Journal:  JCI Insight       Date:  2019-06-11

5.  Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.

Authors:  Stefanie Maurer; Korbinian Nepomuk Kropp; Gerd Klein; Alexander Steinle; Sebastian P Haen; Juliane S Walz; Clemens Hinterleitner; Melanie Märklin; Hans-Georg Kopp; Helmut Rainer Salih
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

6.  Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Authors:  Cristina Maccalli; Diana Giannarelli; Carla Chiarucci; Ornella Cutaia; Gianluca Giacobini; Wouter Hendrickx; Giovanni Amato; Diego Annesi; Davide Bedognetti; Maresa Altomonte; Riccardo Danielli; Luana Calabrò; Anna Maria Di Giacomo; Francesco M Marincola; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2017-05-08       Impact factor: 8.110

7.  Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.

Authors:  Hidehiro Tajima; Isamu Makino; Yoshinao Ohbatake; Shinichi Nakanuma; Hironori Hayashi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hiroyuki Takamura; Tetsuo Ohta
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

8.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

9.  Expression of MICA in oral squamous carcinoma cells and its effect on NK cells.

Authors:  Shunjin Chen; Mingang Ying; Xiuan Lin; Xiong Zheng; Chang Liu; Hui Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.

Authors:  Yan Chen; Bei Chen; Ti Yang; Weiming Xiao; Li Qian; Yanbing Ding; Mingchun Ji; Xiaoqun Ge; Weijuan Gong
Journal:  Cell Mol Immunol       Date:  2015-09-14       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.